Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis


Kazuhiko Kotani, MD, PhD | Amirhossein Sahebkar, PharmD | Maria-Corina Serban, MD, PhD | Sorin Ursoniu, MD, PhD | Dimitri P. Mikhailidis, BSc, MSc, MD | Giovanni Mariscalco, MD, PhD | Steven R. Jones, MD | Seth Martin, MD | Michael J. Blaha, MD | Peter P. Toth, MD | Manfredi Rizzo, MD, PhD | Karam Kostner, MD, PhD | Jacek Rysz, MD, PhD | Maciej Banach, MD, PhD, FNLA, FAHA, FESC, FASA | Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
First published:  September 29, 2016 |


Circulating markers relevant to the development of abdominal aortic aneurysm (AAA) are currently required. Lipoprotein(a), Lp(a), is considered a candidate marker associated with the presence of AAA. The present meta-analysis aimed to evaluate the association between circulating Lp(a) levels and the presence of AAA. The PubMed-based search was conducted up to April 30, 2015, to identify the studies focusing on Lp(a) levels in patients with AAA and controls. Quantitative data synthesis was performed using a random effects model, with standardized mean difference (SMD) and 95% confidence interval (CI) as summary statistics. Overall, 9 studies were identified. After a combined analysis, patients with AAA were found to have a significantly higher level of Lp(a) compared to the controls (SMD: 0.87, 95% CI: 0.41-1.33, P < .001). This result remained robust in the sensitivity analysis, and its significance was not influenced after omitting each of the included studies from the meta-analysis. The present meta-analysis confirmed a higher level of circulating Lp(a) in patients with AAA compared to controls. High Lp(a) levels can be associated with the presence of AAA, and Lp(a) may be a marker in screening for AAA. Further studies are needed to establish the clinical utility of measuring Lp(a) in the prevention and management of AAA.

  1. Moll F, Powell J, Fraedrich G, et al. European Society for Vascular Surgery. Management of abdominal aortic aneurysms clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2011;41(suppl 1):S1–S58.
  2. Davis FM, Rateri DL, Daugherty A. Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies. Heart. 2014;100(19):1498–1505.
  3. Weiss N, Rodionov RN, Mahlmann A. Medical management of abdominal aortic aneurysms. VASA. 2014;43(6):415–421.
  4. Li X, Zhao G, Zhang J, Duan Z, Xin S. Prevalence and trends of the abdominal aortic aneurysms epidemic in general population-a meta-analysis. PloS One. 2013;8(12):e81260.
  5. Stather P, Sidloff D, Dattani N, et al. Meta-analysis and meta-regression analysis of biomarkers for abdominal aortic aneurysm. Br J Surg. 2014;101(11):1358–1372.
  6. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular. 2009;17(5):253–263.
  7. Pejkic S, Opacic D, Mutavdzic P, Radmili O, Krstic N, Davidovic L. Chronic complete thrombosis of abdominal aortic aneurysm: an unusual presentation of an unusual complication. Vascular. 2015;23(1):83–88.
  8. de la Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E. Lipoprotein Lp (a) and atherothrombotic disease. Arch Med Res. 2000;31(4):353–359.
  9. Thompson GR, Seed M. Lipoprotein (a): the underestimated cardiovascular risk factor. Heart. 2014;100(7):534–535.
  10. Lippi G, Franchini M, Targher G. Screening and therapeutic management of lipoprotein (a) excess: review of the epidemiological evidence, guidelines and recommendations. Clin Chim Acta. 2011;412(11):797–801.
  11. Takagi H, Manabe H, Kawai N, Goto S, Umemoto T. Circulating lipoprotein (a) concentrations and abdominal aortic aneurysm presence. Interact Cardiovasc Thorac Surg. 2009;9(3):467–470.
  12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
  13. Simoni G, Gianotti A, Ardia A, Baiardi A, Galleano R, Civalleri D. Screening study of abdominal aortic aneurysm in a general population: lipid parameters. Vascular. 1996;4(4):445–448.
  14. Franks P, Edwards R, Greenhalgh R, Powell J. Risk factors for abdominal aortic aneurysms in smokers. Eur J Vasc Endovasc Surg. 1996;11(4):487–492.
  15. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem. 1986;32(1):142–145.
  16. Norrgård O, Angquist K-A, Dahlen G. High concentrations of Lp (a) lipoprotein in serum are common among patients with abdominal aortic aneurysms. Int Angiol. 1987;7(1):46–49.
  17. Papagrigorakis E, Iliopoulos D, Asimacopoulos P, et al. Lipoprotein (a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet. 1997;52(5):262–271.
  18. Watt HC, Law MR, Wald NJ, Craig WY, Ledue TB, Haddow JE. Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. Int J Epidemiol. 1998;27(6):949–952.
  19. Schillinger M, Domanovits H, Ignatescu MM, et al. Lipoprotein (a) in patients with aortic aneurysmal disease. J Vasc Surg. 2002;36(1):25–30
  20. Sofi F, Marcucci R, Giusti B, et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost. 2005;94(5):1094–1098.
  21. Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein (a) indicates risk for 4 distinct forms of vascular disease. Clin Chem. 2007;53(4):679–685.
  22. Galora S, Saracini C, Palombella AM, et al. Low-density lipoprotein receptor-related protein 5 gene polymorphisms and genetic susceptibility to abdominal aortic aneurysm. J Vasc Surg. 2013;58(4):1062–1068.e1.
  23. Wells G, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Web site. Accessed December 14, 2015. 2000.
  24. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 2. Englewood, NJ: Biostat; 2005:104.
  25. JAMA: Système International (SI) Conversion Factors for Selected Laboratory Components. Web site. Accessed December 7, 2015.
  26. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.
  27. Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013;32(4):188–198.
  28. Sahebkar A. Are Curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta- analysis. Phytother Res. 2014;28(5):633–642.
  29. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.
  30. Wiesner P, Tafelmeier M, Chittka D, et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein (a) in human plasma. J Lipid Res. 2013;54(7):1877–1883.
  31. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011;5(5):673–694.
  32. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54(10):2815–2830
  33. Folsom AR, Yao L, Alonso A, et al. Circulating biomarkers and abdominal aortic aneurysm incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;132(7):578–585.
  34. Ichikawa T, Unoki H, Sun H, et al. Lipoprotein (a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo (a) transgenic rabbits. Am J Pathol. 2002;160(1):227–236
  35. Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb Vasc Biol. 1994;14(3):438–442.
  36. Poon M, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein (a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet. 1997;52(5):308–313.
  37. Boffa MB, Koschinsky ML. Update on lipoprotein (a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep. 2013;15(10):1–10.
  38. Petersen E, Wågberg F, Ängquist K-A. Does lipoprotein (a) inhibit elastolysis in abdominal aortic aneurysms? Eur J Vasc Endovasc Surg. 2003;26(4):423–428.
  39. Bown MJ, Jones GT, Harrison SC, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011;89(5):619–627.
  40. Giusti B, Rossi L, Lapini I, et al. Gene expression profiling of peripheral blood in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2009;38(1):104–112.
  41. Jones GT, Bown MJ, Gretarsdottir S, et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13. 3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet. 2013;22(14):2941–2947.
  42. Harrison SC, Smith AJ, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707–3716.
  43. Hinterseher I, Tromp G, Kuivaniemi H. Genes and abdominal aortic aneurysm. Ann Vasc Surg. 2011;25(3):388–412.
  44. Jones GT, Thompson AR, van Bockxmeer FM, et al. Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol. 2008;28(4):764–770.
  45. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722–729
  46. Strauss E, Oszkinis G, Staniszewski R. SEPP1 gene variants and abdominal aortic aneurysm: gene association in relation to metabolic risk factors and peripheral arterial disease coexistence. Sci Rep. 2014;4:7061.
  47. Biros E, Norman PE, Jones GT, et al. Meta-analysis of the association between single nucleotide polymorphisms in TGF-β receptor genes and abdominal aortic aneurysm. Atherosclerosis. 2011;219(1):218–223
  48. Deguara J, Burnand KG, Berg J, et al. An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Hum Mol Genet. 2007;16(24):3002–3007.
  49. Kostner KM, März W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J. 2013;34(42):3268–3276.
  50. Bos S, Yayha R, van Lennep JER. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014;25(6):452–460.Schmitz G, Orsó E. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl. 2015;10:21–25.
  51. Yoshimura K, Nagasawa A, Kudo J, et al. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int J Mol Sci. 2015;16(5):11213–11228.
  52. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117(14):1883–1889.
  53. Kotani K, Sahebkar A, Serban C, et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015;242(1):87–96.
  54. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721.
  55. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46(12):1956–1967.
  56. Dati F, Tate JR, Marcovina SM, Steinmetz A; International Federation of Clinical Chemistry and Laboratory Medicine; IFCC Working Group for Lipoprotein(a) Assay Standardization. First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay–Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42(6):670–676.
  57. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.